ProCE Banner Activity

TROPION-Breast01: Efficacy and Safety From Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+/HER2- Advanced Breast Cancer

Conference Coverage

Analysis of the phase III TROPION-Breast01 trial of datopotamab deruxtecan vs chemotherapy in previously treated HR+/HER2- advanced breast cancer showed a PFS benefit with datopotamab deruxtecan regardless of prior duration of CDK4/6 inhibitor therapy or baseline brain metastases, tolerable safety, and improved quality of life vs chemotherapy.

Released: December 11, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.